Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women. It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection. The medication was developed by 1957. It is no longer available.
Property | Value |
---|---|
dbo:abstract |
|
dbo:alternativeName |
|
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:class | |
dbp:component |
|
dbp:drugName |
|
dbp:routesOfAdministration | |
dbp:synonyms |
|
dbp:title | |
dbp:titlestyle |
|
dbp:tradename |
|
dbp:type |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
foaf:name |
|
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of |
|
is foaf:primaryTopic of |